Bruker’s New Platform, a stop for mRNA Drugs and More

Introduction

Bruker Corporation is a known manufacturer of diagnostic solutions, including analytical-derived solutions. The company’s scientific instruments are the lead face of its business development. Bruker makes space for innovations in materials, cellular and molecular research. The research activities are carried out throughout the registered markets, nanotechnology, pharma and life sciences.

Announcement

Bruker Corporation proudly introduced its brand new label-free characterisation platform, iNTApharma. This new platform offers individual particle sensitivity for the ample of well-polished and promising analysis of nanoscale bioparticles in familiar aqueous media. This remarkable inauguration of iNTApharma was first revealed at SLAS 2026 in Boston.

New Platforms’ Ability

The iNTApharma serves well-focused and size-based single particle sensitivity quickly in minutes. This contributes to the quality control, therapy development and research operations. This operation needs a proper familiarised evaluation of bio-nanoparticle individuals with no chemical or labelling trim. Whereas, the quantitative specification of bioparticles under the native supervision and prompt conditions is fundamental in lipid nanoparticle (LNP) formulation, lentiviral vector analysis, adenovirus (AdV and AAV) development and extracellular vesicle (EV) research for providing nucleic acid.

This platform is like a helping hand in biopharma quality control (QC), as the Native-state nanoparticle is essential in the QC. Alongside cell and gene therapy and mRNA drug development, the accuracy call is more in demand, to which native-state specification of popular vectors, different nanoscale bioparticles and LNPs demand is also at peak. The iNTApharma has smartly cracked the solutions for these requirements and takes honor to offer its excellence to the vast biological matrices. The iNTApharma is mainly refined for bioparticles measuring from 50 to 300 nanometers.

It allows heterogeneous samples analysis and the resolution of data of subpopulations within the blend. The platform is bricked on the optical measurement idea established in Erlangen, Germany, at the Max-Planck-Institute for the Science of Light (MPL). The same measurement and theory are utilised in mass photometry (MP). The platform is like a close study, translating the modern interferometric scattering (iSCAT) detection technique. This technique is represented as therapy development, QC environments and research as an accessible instrument.

Director at the MPL, Germany, Prof. Vahid Sandoghdar, said, “This technology is formed following the iSCAT microscopy. This microscopy is utilized majorly in quantitative label-free investigations with individual molecule sensitivity. The new platform is bringing this potential to all researchers with its tool that will give a deep insightful of the nanoscale bioparticles.”